Mitochondrial-linked de novo pyrimidine synthesis as a regulator of T cell responses
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 736 KB, PDF-dokument
It has been well established that the metabolism of T cells is integral to their functionality. If a T cell cannot generate enough energy or building blocks, it will not be able to exert its cytotoxic properties to eliminate pathogens and cancer cells. Impairment of mitochondrial oxidative phosphorylation is a well-known disruptor of T cell activation. Dihydroorotate dehydrogenase (DHODH) is a rate-limiting component of the de novo synthesis of pyrimidines and its activity is dependent on functional mitochondrial oxidative phosphorylation. In this regard, DHODH inhibitors have long been used in clinical settings for the treatment of autoimmune diseases, as they potently inhibit lymphocyte proliferation. The exact mode-of-action of these inhibitors in T lymphocytes is not yet exactly understood. In this review, we briefly discuss the critical role of mitochondria in T cell functionality. We also describe how de novo pyrimidine biosynthesis is linked to mitochondrial activity. Finally, we summarize our current knowledge of how mitochondrial-linked de novo pyrimidine biosynthesis modulates T cell responses.
Originalsprog | Engelsk |
---|---|
Artikelnummer | E00019 |
Tidsskrift | Immunometabolism (United States) |
Vol/bind | 5 |
Udgave nummer | 1 |
Antal sider | 5 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:
This study was supported by the Danish Cancer society (R306-A17961 to MJWP) and Nordea-Fonden (to CD).
Publisher Copyright:
Copyright © 2023 The Author(s), Published by Wolters Kluwer Health, Inc.
Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk
Ingen data tilgængelig
ID: 375725139